Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for acute treatment of status migraine
ISRCTN59164978Phase 3Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eptinezumab in migraine, sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Pain relief at 120 minutes. Started Jul 2026; status: recruiting.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on ISRCTN59164978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59164978.